Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEMOPROVE: Voxelotor for hemolysis and organ damage in sickle cell disease
2024-513096-41-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary: Improvement of intravascular hemolysis. Started Aug 2024; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-513096-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513096-41-00.